Viatris (VTRS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$18.97-1.30%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
QuarterlyIQ Insights · VTRS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -8.4% |
| Our one-year growth estimate | diamond | 3.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 11.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 8 industry peers · Company calendar date is not available
VTRS — credit agreement
Dated 2026-07-01
Entry into a Material Definitive Agreement. On July 1, 2026 (the “Closing Date”), Viatris Inc. (“Viatris”) entered into an amended and restated term loan credit agreement (the “Amended and Restated Term Loan Credit Agreement”), among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as administrative agent. The Amended and Restated Term Loan Credit Agreement provides for a ¥40,000,000,000 principal amount senior unsecur…
Why it matters: Viatris raised its 2026 guidance midpoints after strong first-half results. Q3 results will test that higher outlook.
Watch forOn Nov. 5, Viatris keeps its 2026 guidance, including $14.75 billion in revenue and $4.4 billion in adjusted EBITDA.
Also watch forOn Nov. 5, Viatris cuts its 2026 guidance or reports results below its prior outlook.
Why it matters: Management tied its cost review to $600 million to $700 million in yearly savings. Results below that range would weaken the cost plan.
Watch forViatris reports at least $600 million in yearly savings from its company-wide review.
Also watch forViatris reports yearly savings below $600 million or cuts the savings target.
Why it matters: FDA approval would open a new pain product opportunity. A rejection or delay would push that opportunity out.
Watch forFDA approves MR-107A-02 by its Dec. 27, 2026 PDUFA goal date.
Also watch forFDA rejects the application or does not act by Dec. 27, 2026.
Why it matters: Nashik plant issues may limit product supply. A larger hit would add pressure to revenue and guidance.
Worry ifViatris reports that Nashik supply issues cut second-half 2026 revenue by more than $150 million.
Less concerning ifViatris reports a supply hit of $100 million or less, or says the plant issues did not worsen.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$104 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $240 loss on $10,000 · 2.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,897 loss on $10,000 · 19.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New product sales support the growth plan. Viatris reported $172 million for the first half and targets $450 million to $550 million for 2026.
Watch forViatris reports at least $450 million in new product revenue for full-year 2026.
Also watch forViatris reports less than $450 million in new product revenue for full-year 2026.